Novo Nordisk closes the gap in the GLP-1 market! EU approval for higher-dose Wegovy pen received!
Reading Time: 3 minutes
Comeback underway! Novo Nordisk is closing the gap with the Wegovy pill, surpassing Eli Lilly with 18,410 US prescriptions in January Reimbursement success! France becomes the first EU country to permanently cover costs for obesity medications in cases of severe obesity Pipeline expansion! The EU approval for a higher dose 7.2 mg Wegovy pen and new data on CagriSema strengthen market position A disappointing outlook burdened the stock price of Novo Nordisk (NVO) at the beginning of 2026. However, just in time for the scientific meetings...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
